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1. INTRODUCTION {#dom13038-sec-0005}
===============

Over the past decade, several classes of oral glucose‐lowering agents have been launched, including dipeptidyl peptidase‐4 (DPP‐4) inhibitors and sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors.[1](#dom13038-bib-0001){ref-type="ref"} DPP‐4 inhibitors increase levels of the active forms of glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide after food intake, which in turn promote insulin secretion and suppress glucagon secretion. Because these mechanisms are glucose‐dependent, the risk of hypoglycaemia is low.[1](#dom13038-bib-0001){ref-type="ref"}, [2](#dom13038-bib-0002){ref-type="ref"} SGLT2 inhibitors suppress glucose reabsorption in the renal tubules and exert antihyperglycaemic effects in an insulin‐independent manner. This class of drug reduces both blood glucose levels and body weight[1](#dom13038-bib-0001){ref-type="ref"}, [3](#dom13038-bib-0003){ref-type="ref"}; however, it has been reported that SGLT2 inhibitors cause a rise in glucagon levels and enhance gluconeogenesis.[3](#dom13038-bib-0003){ref-type="ref"}, [4](#dom13038-bib-0004){ref-type="ref"}, [5](#dom13038-bib-0005){ref-type="ref"} Owing to these differences in their mechanisms of action, the combined use of both types of inhibitor has been reported to be beneficial because they act in a complementary manner,[6](#dom13038-bib-0006){ref-type="ref"}, [7](#dom13038-bib-0007){ref-type="ref"} and 2 fixed‐dose combination products have been launched in Western countries.[7](#dom13038-bib-0007){ref-type="ref"}

Diabetes mellitus is caused by impaired insulin secretion and insulin resistance[8](#dom13038-bib-0008){ref-type="ref"}; however, there are differences in the pathology of type 2 diabetes mellitus (T2DM) between Japanese and Caucasian subjects. The dominant pathology in Japanese individuals is impaired insulin secretion, while that in Caucasian individuals is insulin resistance.[2](#dom13038-bib-0002){ref-type="ref"}, [9](#dom13038-bib-0009){ref-type="ref"} Although metformin is the first‐line drug in Western countries,[10](#dom13038-bib-0010){ref-type="ref"} the use of DPP‐4 inhibitors has been increasing in Japan: according to an analysis of the Japan Medical Data Centre Claims Database (Japan Medical Data Centre Co. Ltd, Tokyo, Japan), \~70% of Japanese patients with T2DM use DPP‐4 inhibitors, and \~60% of patients receiving DPP‐4 inhibitors are drug‐naïve.[2](#dom13038-bib-0002){ref-type="ref"} In some cases, however, it is difficult to control blood glucose using a DPP‐4 inhibitor alone.[11](#dom13038-bib-0011){ref-type="ref"}, [12](#dom13038-bib-0012){ref-type="ref"}, [13](#dom13038-bib-0013){ref-type="ref"} In such cases, combining a DPP‐4 inhibitor with an SGLT2 inhibitor is a possible option, but this combination has yet to be fully evaluated in Japanese patients. Owing to the differences in T2DM pathology and treatment algorithms between Japanese and Western populations, the results of studies examining combination therapy with a DPP‐4 inhibitor and an SGLT2 inhibitor in Western patients may not be generalizable to Japanese patients; therefore, it is important to examine the efficacy and safety of this combination in Japanese patients.

The DPP‐4 inhibitor teneligliptin has been approved in Japan and Korea for the treatment of T2DM.[14](#dom13038-bib-0014){ref-type="ref"}, [15](#dom13038-bib-0015){ref-type="ref"} The 1‐year efficacy and safety of teneligliptin as monotherapy and in combination with oral antidiabetic drugs (other than SGLT2 inhibitors) in Japanese patients with T2DM have been evaluated.[16](#dom13038-bib-0016){ref-type="ref"}, [17](#dom13038-bib-0017){ref-type="ref"} In addition, its combination with metformin was evaluated in a European multicentre study.[18](#dom13038-bib-0018){ref-type="ref"} Canagliflozin is an SGLT2 inhibitor approved for the treatment of T2DM in North America, Latin America, Europe and the Asia‐Pacific region, including Japan.[19](#dom13038-bib-0019){ref-type="ref"} A recently completed 24‐week, double‐blind study demonstrated the safety and efficacy, including during a mixed‐meal tolerance test, of canagliflozin add‐on therapy to teneligliptin in Japanese patients with T2DM who had inadequate glycaemic control on teneligliptin monotherapy.[20](#dom13038-bib-0020){ref-type="ref"} In the present study, we report the safety and efficacy of teneligliptin and canagliflozin combination therapy, including the results of mixed‐meal tolerance tests and subgroup analyses according to patient characteristics, over the longer term (52 weeks) in patients with inadequate glycaemic control on teneligliptin alone. In addition, because of the increasing recognition of the importance of composite endpoints in T2DM trials,[21](#dom13038-bib-0021){ref-type="ref"} the percentage of patients with decreases in both glycated haemoglobin (HbA1c) and body weight at the end of treatment was evaluated in a *post hoc* analysis.

2. MATERIALS AND METHODS {#dom13038-sec-0006}
========================

2.1. Study design {#dom13038-sec-0007}
-----------------

This 52‐week, open‐label study was performed in 24 institutions in Japan. The participating institutions/investigators are listed in Appendix S1.

2.2. Patients {#dom13038-sec-0008}
-------------

The study included Japanese patients with T2DM with inadequate glycaemic control on teneligliptin and diet and exercise therapy. The inclusion criteria were as follows: age ≥20 years; glycated haemoglobin (HbA1c) ≥7.0% and \<10.5%; fasting plasma glucose (FPG) concentration ≤270 mg/dL; and diet and exercise therapy for diabetes for \>12 weeks before the treatment period. Patients meeting the following criteria at the screening visit were excluded from the study: type 1 diabetes; diabetes mellitus resulting from a pancreatic disorder, or secondary diabetes; serious complications of diabetes; hereditary glucose‐galactose malabsorption or primary renal glucosuria; class III/IV heart failure symptoms according to the New York Heart Association functional classification; and severe hepatic or severe renal disorder.

2.3. Interventions {#dom13038-sec-0009}
------------------

Patients underwent a washout period of \>12 weeks in which they stopped all antidiabetic drugs, except for teneligliptin, before the treatment period. Patients continued their fixed programme of diet and exercise therapy during the washout period. Teneligliptin and canagliflozin were orally administered at doses of 20 and 100 mg, respectively (the approved doses in Japan), once daily before breakfast for 52 weeks. Diet and exercise therapy continued unchanged during the treatment period. A 2‐week observation period followed the treatment period. Mixed‐meal tolerance tests were performed at baseline, week 24 and week 52 using a method similar to that reported in a previous study.[20](#dom13038-bib-0020){ref-type="ref"} Visits were scheduled every 4 weeks during the treatment period, and at 2 weeks after study completion or at study withdrawal (if before week 52).

2.4. Outcomes {#dom13038-sec-0010}
-------------

The safety evaluation included assessments of adverse events (AEs), hypoglycaemia, laboratory values, ECG, and vital signs. AEs and safety assessments were recorded throughout the study by the study investigators, and were not limited to the time of hospital visits. AEs were listed using Medical Dictionary for Regulatory Activities (Version 18.1) system organ class and preferred terms, and their potential relationships to the study drug (no causal relationship or a possible causal relationship, ie, adverse drug reactions; ADRs) and severity (mild, moderate or severe) were assessed.

The efficacy evaluation included the following assessments: change from baseline in HbA1c, FPG, body weight, proinsulin/C‐peptide ratio and homeostatis model assessment 2 steady state beta‐cell function (HOMA2‐%B) values; and evaluation of postprandial glucose, glucagon and C‐peptide at weeks 24 and 52 in the mixed‐meal tolerance test. HbA1c was measured by high‐performance liquid chromatography using a reference standard approved by the US National Glycohemoglobin Standardization Program. Glucagon was measured by radioimmunoassay (SCETI K.K., Tokyo, Japan). All efficacy and safety laboratory measurements were assayed at a central laboratory (LSI Medience Corporation, Tokyo, Japan). Prespecified subgroup analyses were performed to evaluate the safety and efficacy of this combination therapy in patients subdivided on the basis of the following background factors: HbA1c \<8% and ≥8%; body mass index (BMI) \<25 and ≥25 kg/m^2^; and estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m^2^, ≥60 to \<90 mL/min/1.73 m^2^ and ≥90 mL/min/1.73 m^2^.

2.5. Statistical methods {#dom13038-sec-0011}
------------------------

Safety analyses were performed in the safety analysis set, which comprised all patients, excluding those who did not receive a dose of the study drug or who lacked safety data after starting administration of the study drug. Efficacy analyses were performed in the full analysis set, which comprised all patients, excluding those who did not receive a dose of the study drug or who had no efficacy data after starting administration of the study drug. Descriptive statistics of values measured at each time point and at the end of the treatment period were calculated for each variable. Changes in efficacy variables from baseline to week 52 were determined using the last observation carried forward (LOCF) to impute missing values. Descriptive statistics and 95% confidence intervals (CIs) were calculated for changes or percent changes from baseline to each measurement time point and the end of the treatment period. HbA1c \<7.0% and \<8.0% success rates and 95% CI (based on the F distribution) at the end of the treatment period were calculated. Using individual patient data, the correlation between changes in HbA1c and body weight from baseline and a composite endpoint (the percentage of patients with decreases in both HbA1c and body weight) at the end of the treatment period were evaluated in *post hoc* analyses. Owing to the descriptive nature of the analyses, *P* values were not calculated. All statistical analyses were performed using Windows SAS version 9.2 or later.

2.6. Ethical considerations {#dom13038-sec-0012}
---------------------------

The trial was registered at [clinicaltrials.gov](http://clinicaltrials.gov/) (identifier NCT02220907), and was carried out in accordance with the ethical principles of the Declaration of Helsinki, the Law for Ensuring the Quality, Efficacy, and Safety of Drugs and Medical Devices, Good Clinical Practice guidelines, and the approved study protocol practice. The study was approved by the ethics committee/institutional review boards at all participating institutions (Appendix S1). All patients provided written informed consent.

3. RESULTS {#dom13038-sec-0013}
==========

3.1. Patients {#dom13038-sec-0014}
-------------

Of the 200 patients who consented to participate, 153 entered the treatment period and 142 completed the study. All 153 patients were included in the full analysis set and safety analysis set. Patient characteristics are described in Table [1](#dom13038-tbl-0001){ref-type="table-wrap"}. Of the 153 patients, 108 (70.6%) were men. The mean ± standard deviation (s.d.) age and BMI were 56.1 ± 10.4 years and 26.52 ± 4.47 kg/m^2^, respectively. The mean ± s.d. baseline HbA1c and FPG were 8.14% ± 0.94% and 177.3 ± 34.8 mg/dL, respectively.

###### 

Demographics and baseline characteristics (safety analysis set/full analysis set; N = 153)

  Variable                                         Value
  ------------------------------------------- ---------------
  Sex, n (%)                                  
  Men                                           108 (70.6)
  Women                                          45 (29.4)
  Age(years), mean(s.d)                         56.1 (10.4)
  Duration of diabetes(years), mean(s.d.)       9.07 (5.55)
  Body weight (kg), mean(s.d.)                 72.12 (14.87)
  BMI (kg/m^2^), mean(s.d.)                    26.52 (4.47)
  Diabetic complications, n (%)               
  Total                                          68 (44.4)
  Diabetic retinopathy                           24 (15.7)
  Diabetic neuropathy                            16 (10.5)
  Diabetic nephropathy                           51 (33.3)
  Non‐diabetic complications, n (%)           
  Hypertension                                   89 (58.2)
  Hyperlipidaemia                               128 (83.7)
  HbA1c (%), mean(s.d.)                         8.14 (0.94)
  Fasting plasma glucose(mg/dL), mean(s.d.)    177.3 (34.8)
  eGFR(mL/min/1.73m^2^), mean(s.d.)             86.7 (19.2)

^a^Fasting plasma glucose: 1 mg/dL = 0.0555 mmol/L.

3.2. Safety {#dom13038-sec-0015}
-----------

A summary of the AEs is shown in Table [2](#dom13038-tbl-0002){ref-type="table-wrap"}. The overall incidence of AEs and ADRs at 52 weeks was 69.9% (107/153 patients; 269 events) and 22.9% (35/153 patients; 45 events), respectively. There were 13 serious AEs in 11 patients, including one ADR in one patient. The serious AEs observed were cataract, myocardial infarction, ankle fracture, influenza, pneumonia, disseminated herpes zoster, rectal cancer, hepatocellular carcinoma, atrial fibrillation and sinus node dysfunction. A serious ADR of myocardial infarction occurred in 1 patient.

###### 

Adverse events occurring during the study (safety analysis set, N = 153)

  AEs                                               n (%)
  --------------------------------------------- -------------
  AEs                                            107 (69.9)
  Drug‐related AEs                                35 (22.9)
  Serious AEs                                     11 (7.2)
  Serious drug‐related AEs                         1 (0.7)
  AEs leading to discontinuation                   7 (4.6)
  Drug‐related AEs leading to discontinuation      3 (2.0)
  AEs of special interest                       
  Documented hypoglycaemia                         4 (2.6)
  Osmotic diuresis                                15 (9.8)
  Volume depletion                                 2 (1.3)
  Genital infection (males)                      1/108 (0.9)
  Genital infection (females)                    5/45 (11.1)
  Urinary tract infection                          2 (1.3)
  Fracture                                         3 (2.0)
  Blood ketone body increased                      3 (2.0)
  Hepatic function impairment                      2 (1.3)
  Skin and subcutaneous tissue disorders          13 (8.5)
  Cardiovascular‐related events                    3 (2.0)
  Malignant neoplasm                               2 (1.3)
  Gastrointestinal disorders                      23 (15.0)

A total of 9 AEs, including 4 ADRs, led to discontinuation in 7 and 3 patients, respectively. AEs that led to discontinuation were myocardial infarction, vulvar vaginal candidiasis, rectal cancer, hepatocellular carcinoma, atrial fibrillation, sinus node dysfunction, eczema and balanoposthitis. ADRs that led to discontinuation were vulvar vaginal candidiasis, myocardial infarction, eczema and balanoposthitis. No AEs resulted in death during the study.

Table [2](#dom13038-tbl-0002){ref-type="table-wrap"} shows the AEs of special interest. No other AEs of special interest were observed. For canagliflozin, the AEs included ketoacidosis and sepsis. For teneligliptin, the AEs were intestinal obstruction and interstitial pneumonia. Laboratory values are presented in Table S1, Appendix S1.

3.3. Efficacy {#dom13038-sec-0016}
-------------

A decrease in HbA1c from baseline to week 52 (LOCF) was observed, with a mean change of −0.99% (95% CI −1.12 to −0.85; Table [3](#dom13038-tbl-0003){ref-type="table-wrap"}). The decrease in HbA1c was apparent at week 4; HbA1c then continued to decrease to week 12, gradually decreased thereafter, and its level was maintained until week 52 (Figure [1](#dom13038-fig-0001){ref-type="fig"}A). The proportions of patients who achieved HbA1c \<7% and HbA1c \<8% at week 52 were 43.75% (95% CI 35.51--52.26) and 72.37% (95% CI 60.91--82.01), respectively. A decrease in FPG was detected by week 4 and was maintained until week 52 (Figure [1](#dom13038-fig-0001){ref-type="fig"}B). The mean change in FPG from baseline to week 52 (LOCF) was −38.6 mg/dL (95% CI −43.4 to −33.9; Table [3](#dom13038-tbl-0003){ref-type="table-wrap"}). A decrease in body weight was detected by week 4. Body weight continued to decrease until week 20 and was maintained until week 52 (Figure [1](#dom13038-fig-0001){ref-type="fig"}C). The change and percent change in body weight from baseline to week 52 (LOCF) were −2.86 kg (95% CI −3.42 to −2.31) and −3.92% (95% CI −4.53 to −3.31), respectively (Table [3](#dom13038-tbl-0003){ref-type="table-wrap"}). Figure [1](#dom13038-fig-0001){ref-type="fig"}D is a scatter plot of the change in HbA1c vs the percent change in body weight from baseline to week 52 (LOCF). As indicated in this figure, decreases in both HbA1c and body weight occurred in 82.24% of patients. The change in HbA1c was not correlated with the percent change in body weight (*r* = 0.2778).

###### 

Effects of canagliflozin and teneligliptin combination therapy on efficacy endpoints (full analysis set, N = 153)

  Variable                                           Value
  -------------------------------------------------- --------------------------------------------------------
  HbA1c, % (*n* = 153)                               
  Baseline, mean (s.d.)                              8.14 (0.94)
  Change from baseline (LOCF), mean (s.d.)           −0.99 (0.84)
  95% CI                                             −1.12 to −0.85
  FPG, mg/dL (*n* = 152)                             
  Baseline, mean (s.d.)                              177.1 (34.8)[a](#dom13038-note-0002){ref-type="fn"}
  Change from baseline (LOCF), mean (s.d.)           −38.6 (1.66)
  95% CI                                             −2.14 to −1.88
  Body weight, kg (*n* = 152)                        
  Baseline, mean (s.d.)                              72.08 (14.91)[a](#dom13038-note-0002){ref-type="fn"}
  Change from baseline (LOCF), mean (s.d.)           −2.86 (3.46)
  95% CI                                             −3.42 to −2.31
  Percent change from baseline (LOCF), mean (s.d.)   −3.92 (3.81)
  95% CI                                             −4.53 to −3.31
  Fasting proinsulin/C‐peptide ratio (*n* = 152)     
  Baseline, mean (s.d.)                              0.0197 (0.0114)[a](#dom13038-note-0002){ref-type="fn"}
  Change from baseline (LOCF), mean (s.d.)           −0.0047 (0.0073)
  95% CI                                             −0.0059 to −0.0036
  HOMA2‐%B, % (*n* = 152)                            
  Baseline, mean (s.d.)                              35.00 (16.53)[a](#dom13038-note-0002){ref-type="fn"}
  Change from baseline (LOCF), mean (s.d.)           10.91 (13.23)
  95% CI                                             8.79 to 13.03
  Fasting glucagon, pg/mL (*n* = 152)                
  Baseline, mean (s.d.)                              125.3 (21.8)[a](#dom13038-note-0002){ref-type="fn"}
  Change from baseline (LOCF), mean (s.d.)           −0.6 (22.1)
  95% CI                                             −4.1 to 2.9

Baseline mean (s.d.) values for the population with LOCF data.

^b^FPG: 1 mg/dL = 0.0555 mmol/L. Glucagon: 1 pg/mL = 1 ng/L.

![Changes in A, HbA1c; B, FPG and C, body weight from baseline during the study period. Data represent mean (95% CI). D, Scatter plot of the change in HbA1c vs percent change in body weight from baseline to the end of treatment in individual patients. FPG: 1 mg/dL = 0.0555 mmol/L.](DOM-20-77-g001){#dom13038-fig-0001}

Regarding other efficacy endpoints, the mean changes in the fasting proinsulin/C‐peptide ratio and HOMA2‐%B values from baseline to week 52 (LOCF), as markers of β‐cell function, were −0.0047 (95% CI −0.0059 to −0.0036) and 10.91% (95% CI 8.79‐13.03), respectively (Table [3](#dom13038-tbl-0003){ref-type="table-wrap"}). Other efficacy endpoints, including the changes from baseline to week 52 (LOCF) for systolic and diastolic blood pressure, triglycerides and HDL cholesterol, are summarized in Table S2, Appendix S1. Systolic and diastolic blood pressure was decreased and HDL cholesterol increased during this time. Figure [2](#dom13038-fig-0002){ref-type="fig"} shows the results of the mixed‐meal tolerance test, with actual values of glucose, C‐peptide and glucagon after the meal at baseline, week 24 and week 52. As shown in Figure [2](#dom13038-fig-0002){ref-type="fig"}A, plasma glucose values measured at 0, 0.5, 1 and 2 hours were substantially lower at weeks 24 and 52 than at baseline. The changes in 2‐hour postprandial glucose from baseline to weeks 24 and 52 were −63.3 mg/dL (95% CI −71.5 to −55.0) and −60.7 mg/dL (95% CI −69.9 to −51.5), respectively (Table S3, Appendix S1). The time courses of plasma C‐peptide and glucagon were similar after treatment compared with baseline except that glucagon at each time point was lower at week 24 (Figure [2](#dom13038-fig-0002){ref-type="fig"}B,C). The mixed‐meal tolerance test also showed decreases from baseline in area under the curve (AUC)~0‐2h~ at weeks 24 and 52 in postprandial plasma glucose (Table S3, Appendix S1). Although the postprandial C‐peptide AUC~0‐2h~ did not increase after treatment, the C‐peptide AUC~0‐2h~/blood glucose AUC~0‐2h~ ratio showed an increase from baseline at weeks 24 and 52. The postprandial glucagon AUC~0‐2h~ was decreased at week 24, and the difference became smaller at week 52. The incremental 2‐hour postprandial plasma glucose and incremental postprandial plasma glucose AUC~0‐2h~ decreased, while the incremental C‐peptide AUC~0‐2h~/blood glucose AUC~0‐2h~ ratio increased at weeks 24 and 52 compared with baseline (Table S3, Appendix S1).

![Changes in A, blood glucose; B, C‐peptide and C, glucagon levels in the mixed‐meal tolerance tests at baseline, week 24 and week 52. Data represent mean ± standard deviation. Glucose: 1 mg/dL = 0.0555 mmol/L; C‐peptide: 1 ng/mL = 0.333 nmol/L; Glucagon: 1 pg/mL = 1 ng/L.](DOM-20-77-g002){#dom13038-fig-0002}

3.4. Subgroup analyses of safety and efficacy according to background characteristics {#dom13038-sec-0017}
-------------------------------------------------------------------------------------

The results of the prespecified subgroup analysis according to baseline HbA1c, BMI and eGFR are shown in Tables S4 and S5, Appendix S1. Because a small number of patients with eGFR \<60 mL/min/1.73 m^2^ were enrolled, no further analysis was possible in this group. The extent of the decrease in HbA1c was greater in subgroups with higher baseline HbA1c (≥8%) and higher baseline eGFR (≥90 mL/min/1.73 m^2^), but the change in HbA1c did not differ among the BMI subgroups. The body weight change (%) did not differ among the subgroups (Table S4, Appendix S1). Baseline HbA1c, BMI and eGFR had no effect on the overall incidence of AEs or ADRs (Table S5, Appendix S1).

4. DISCUSSION {#dom13038-sec-0018}
=============

This study examined the long‐term safety and efficacy of canagliflozin added on to teneligliptin in Japanese patients with T2DM. In particular, we observed no new safety concerns after administering this combination of drugs compared with previous studies of canagliflozin and teneligliptin.[16](#dom13038-bib-0016){ref-type="ref"}, [17](#dom13038-bib-0017){ref-type="ref"}, [22](#dom13038-bib-0022){ref-type="ref"} We also observed reductions in HbA1c, FPG and body weight during the study. These effects were apparent within \~4 weeks of starting treatment, and were maintained for 52 weeks without attenuation. The reduction in postprandial glucose levels was also maintained for 52 weeks.

A recent 24‐week randomized, placebo‐controlled trial examined the safety and efficacy of canagliflozin added on to teneligliptin in Japanese patients with T2DM, and showed that this combination was well tolerated and effective.[20](#dom13038-bib-0020){ref-type="ref"} In that study, the addition of canagliflozin was associated with significant improvements in HbA1c, FPG, body weight and postprandial plasma glucose‐related variables. The present study not only confirms the results of this previous study, but also shows that the improvements in HbA1c, FPG, body weight and postprandial glucose were maintained over a longer time period (52 weeks vs 24 weeks). Similarly to the present study, Inagaki et al.[22](#dom13038-bib-0022){ref-type="ref"} also conducted an open‐label, long‐term (52‐week) study of the safety and efficacy of canagliflozin (100 or 200 mg) as monotherapy or added on to other oral antihyperglycaemic drugs, including DPP‐4 inhibitors (sitagliptin, vildagliptin or alogliptin) in Japan. Other 52‐week studies in Japanese patients examined the safety and efficacy of the SGLT2 inhibitors empagliflozin and dapagliflozin added on to other oral antihyperglycaemic drugs, including DPP‐4 inhibitors. Although some data (eg, postprandial glucose) were not reported, the authors mentioned that an SGLT2 inhibitor in combination with a DPP‐4 inhibitor achieved clinically relevant reductions in HbA1c, and was generally well tolerated.[23](#dom13038-bib-0023){ref-type="ref"}, [24](#dom13038-bib-0024){ref-type="ref"} The safety and efficacy of combinations of SGLT2 inhibitors and DPP‐4 inhibitors have also been investigated in Western patients. For example, a sub‐analysis of the CANVAS trial revealed improvements in HbA1c and body weight when canagliflozin was added on to a DPP‐4 inhibitor or GLP‐1 receptor agonist for 18 weeks.[25](#dom13038-bib-0025){ref-type="ref"} Some longer‐term Western studies have also been conducted in which dapagliflozin was added on to sitagliptin (with or without metformin) for 48 weeks,[26](#dom13038-bib-0026){ref-type="ref"} or saxagliptin was added on to dapagliflozin plus metformin for 52 weeks.[27](#dom13038-bib-0027){ref-type="ref"} The results of those studies in Western patients, together with the results of the present study in Japanese patients, indicate that the combination of an SGLT2 inhibitor with a DPP‐4 inhibitor is likely to be effective in terms of improving and maintaining glycaemic control for the long term in patients with T2DM, and ethnic differences are unlikely to confound the effects of this combination.

The common AEs observed in the present study (ie, those occurring in \>5% of patients) were osmotic diuresis, genital infection (in women), skin disorders and gastrointestinal dysfunction. These AEs have already been reported for canagliflozin added on to teneligliptin[20](#dom13038-bib-0020){ref-type="ref"} and for other DPP‐4 inhibitors.[22](#dom13038-bib-0022){ref-type="ref"}, [25](#dom13038-bib-0025){ref-type="ref"} Nevertheless, almost all of these AEs were mild in severity, and the safety profile for the combination used here did not differ from the known safety profiles of teneligliptin and canagliflozin; therefore, no new risks requiring additional precautions were found during long‐term treatment as compared with monotherapy.

In the mixed‐meal tolerance test conducted in the present study, the decrease in incremental glucose levels suggests that the combination decreased postprandial glucose excursions. No increase in postprandial glucagon was observed, which was consistent with a previous double‐blind study.[20](#dom13038-bib-0020){ref-type="ref"} Although the acute effect of increasing postprandial glucagon was attributed to canagliflozin (300 mg),[28](#dom13038-bib-0028){ref-type="ref"} this finding may have resulted from the use of low doses of canagliflozin (100 mg) or the suppressive effect of teneligliptin, which was reported to supress postprandial glucagon levels.[29](#dom13038-bib-0029){ref-type="ref"} The present study also revealed improvements in HOMA2‐%B and the proinsulin/C‐peptide ratio, which were maintained until week 52, consistent with a recent 24‐week double‐blind study.[20](#dom13038-bib-0020){ref-type="ref"} These results suggest that the combination had sustained effects on β‐cell function. The post‐meal improvement in β‐cell function, in terms of the C‐peptide AUC~0‐2h~/blood glucose AUC~0‐2h~ ratio, was also maintained until week 52. Overall, these findings suggest that the combination decreased postprandial glucose by enhancing glucose excretion and improving β‐cell function, probably by alleviating glucotoxicity.

Another possible mechanism underlying the effect of the combination on postprandial glucose is that it might enhance GLP‐1 secretion. Oral administration of 100 mg of canagliflozin increased plasma total GLP‐1 after breakfast in Japanese patients with T2DM,[30](#dom13038-bib-0030){ref-type="ref"} probably because of a weak inhibitory effect of canagliflozin against SGLT1.[31](#dom13038-bib-0031){ref-type="ref"} Although we did not measure GLP‐1 levels in the present study, the combination of teneligliptin and canagliflozin may increase active GLP‐1 levels, representing a beneficial effect of this combination.

In the present study, which is the first to report subgroup analyses in patients treated with canagliflozin in combination with a DPP‐4 inhibitor, we assessed the safety and efficacy of the combination in patients subdivided into subgroups on the basis of baseline HbA1c, BMI and eGFR. We found that the decrease in HbA1c was greater in subgroups with higher baseline HbA1c and higher baseline eGFR, but did not differ among the BMI subgroups. Moreover, the incidence of AEs was similar in each group. These results are consistent with a previous subgroup analysis of canagliflozin.[32](#dom13038-bib-0032){ref-type="ref"}, [33](#dom13038-bib-0033){ref-type="ref"}

It has been reported that DPP‐4 inhibitors are potentially more effective in Asian than in non‐Asian patients,[34](#dom13038-bib-0034){ref-type="ref"} and in Japanese rather than in non‐Japanese patients,[35](#dom13038-bib-0035){ref-type="ref"} and Asian people are often characterized by a lower BMI than other groups. Meanwhile, DPP‐4 inhibitors may show decreased efficacy in patients with higher BMI.[34](#dom13038-bib-0034){ref-type="ref"} Considering these concepts, SGLT2 inhibitors may be a useful addition to the treatment regimen in patients with higher BMI who respond poorly to a DPP‐4 inhibitor. It has also been reported that body weight management is important for maintaining good long‐term glycaemic control with DPP‐4 inhibitors.[36](#dom13038-bib-0036){ref-type="ref"}, [37](#dom13038-bib-0037){ref-type="ref"} In the present study, the reductions in HbA1c and body weight were maintained for 52 weeks without attenuation, and 82.24% of patients showed decreases in both HbA1c and body weight at the end of the treatment period.

Based on these findings, a DPP‐4 inhibitor combined with an SGLT2 inhibitor represents a useful therapeutic option for Japanese patients with T2DM.

The present study has some limitations that must be acknowledged, including its single‐arm, open‐label design, and the fact that it only included Japanese patients. Long‐term data on the use of this combination in Japanese patients are important, however, particularly when we consider the differences in the pathophysiology, between Japanese and non‐Japanese patients. Importantly, we showed that this combination was effective and well tolerated over a longer period than that in a previous 24‐week randomized controlled trial.[20](#dom13038-bib-0020){ref-type="ref"} Finally, we did not perform statistical hypothesis testing; however, the changes in variables observed are likely to be clinically relevant when we consider the 95% CIs did not cross 0.

In conclusion, the results in this cohort of Japanese patients with T2DM suggest that canagliflozin added on to teneligliptin is tolerable and effective in individuals whose blood glucose levels cannot be sufficiently controlled by teneligliptin monotherapy. This study showed that the improvements in glycaemic control were maintained for the 52‐week study duration.
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